Seeking Alpha·2026-02-19 11:51Carvana (CVNA) - Carvana sold more cars than Wall Street expected in Q4, but concerns over profitability led to a 16% drop in premarket trading [5] - The company experienced a 58% surge in revenue, with retail vehicle sales up 43% and wholesale sales increasing by 66% [5] - However, gross profit per vehicle declined by $244, and adjusted EBITDA of $511 million missed estimates of $539 million [6] - Adjusted profits per share surged to $4.22 from $0.56, but this was attributed to one-time charges and is not comparable to the $1.12 estimates [6] - Carvana did not issue sales guidance for the full year but expects to sell 3 million cars between 2030 and 2035 [7] DoorDash (DASH) - DoorDash shares rose 13% in premarket trading due to strong order growth and upbeat guidance, despite a Q4 miss on both top and bottom lines [7] - Orders climbed 32% to 903 million, and gross order value (GOV) jumped 39% to $29.7 billion, both exceeding expectations [7] - The Q1 outlook for GOV is projected between $31 billion and $31.8 billion, with EBITDA expected to be between $675 million and $775 million [7] Moderna (MRNA) - Moderna shares closed 6% higher after the FDA accepted its marketing application for the mRNA-1010 flu shot, reversing a previous refusal to review [8] - The FDA has set August 5, 2026, as the target action date for the biologics license application (BLA) for mRNA-1010 [9] - Moderna plans to launch mRNA-1010 in the U.S. for adults aged 50 and older for the 2026/2027 flu season [10]